Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Gastric Adenocarcinoma
Interventions: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; Procedure
Lead sponsor: Banner Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Gilbert, Arizona

Conditions: PSC
Interventions: Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Solid Tumor, Lymphoma, Peripheral T-Cell Lymphoma
Interventions: ALRN-6924; Drug
Lead sponsor: Aileron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • Duarte, California • Denver, Colorado + 9 more

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma
Interventions: Stereotactic Body Radiation (SBRT), Nivolumab, CCR2/CCR5 dual antagonist, GVAX; Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Testosterone enanthate, Megestrol acetate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 21
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 12 more

Conditions: HIV
Interventions: Stribild, Atripla; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Rectal Cancer
Interventions: Etrumadenant (AB928), Radiation therapy, FOLFOX regimen, Zimberelimab (AB122); Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 3
States / cities: New York, New York

Conditions: Multiple Brain Metastases
Interventions: BMX-001, Whole Brain Radiation Therapy; Drug · Radiation
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 4
States / cities: Lexington, Kentucky • Detroit, Michigan • Durham, North Carolina + 1 more

Conditions: Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
Interventions: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Oklahoma City, Oklahoma + 1 more

Conditions: Acute Myeloid Leukemia
Interventions: Actinium Ac 225 Lintuzumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Decitabine and Cedazuridine, Venetoclax; Radiation · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HIV Infections
Interventions: Amprenavir, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 8 more

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions: carbidopa-levodopa, Placebo Oral Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Porphyria Cutanea Tarda, Hepatitis C
Interventions: Harvoni; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas

Conditions: Diabetic Foot Ulcer (DFU), Granulation of Chronic Diabetic Wounds
Interventions: an allogenic cell-based product, containing living human bone marrow-derived mesenchymal stem cells (MSCs) and MSCs differentiated into adipocytes on a porous chitosan-gelatin matrix, Standard of Care of Diabetic Foot Ulcers; Drug · Other
Lead sponsor: Ayu, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions: Chemoradiation; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more

Conditions: Drug-Resistant Epilepsy, Focal-Onset Seizures
Interventions: Padsevonil; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 406 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 25
States / cities: Chandler, Arizona • La Jolla, California • San Francisco, California + 21 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Rimonabant, Metformin, placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Cholangitis, Sclerosing
Interventions: Oral all-trans retinoic acid (ATRA); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: New Haven, Connecticut • Rochester, Minnesota

Conditions: HIV-associated Neuropathy, Polyneuropathy
Interventions: SAB378, methadone, SAB placebo, Methadone placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: San Diego, California • Brooklyn, New York • Rochester, New York

Conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions: Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy; Other · Genetic · Drug
Lead sponsor: University of Washington; Other
Eligibility: 3 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-small Cell Lung Cancer
Interventions: Suramin Drug:Docetaxel Drug: Carboplatin, Placebo Drug: Docetaxel Drug: Carboplatin; Drug
Lead sponsor: Optimum Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Richmond, Virginia

Conditions: Neurological Cancer
Interventions: ASTX727; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna, Isatuximab; Drug
Lead sponsor: Indapta Therapeutics, INC.; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Lake Mary, Florida • Atlanta, Georgia + 9 more

Conditions: Acute Myeloid Leukemia
Interventions: Lintuzumab-Ac-225, Cladribine, Cytarabine, Mitoxantrone, G-CSF; Biological · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Milwuakee, Wisconsin

Search by objective public record fields.

PHASE II EVALUATION OF CYTOREDUCTION SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (CRS/HIPEC) IN GASTRIC CANCER

PET/MRI of Primary Sclerosing Cholangitis

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss

Sleep and Cognition After Atripla to Stribild Switch

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis

Harvoni Treatment Porphyria Cutanea Tarda

Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer

ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia